Interaction of ocular hypotensive agents (PGF2 analogs - Bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 6, 2009, Pages 487-497

  Hariharan, Sudharshan ^a   Minocha, Mukul ^a   Mishra, Gyan P ^a   Pal, Dhananjay ^a   Krishna, Rohit ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; ERYTHROMYCIN DERIVATIVE; LATANOPROST; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 5; PREDNISOLONE; TRAVOPROST; VERLUKAST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA PERMEABILITY; DOG; DRUG ACCUMULATION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; EPITHELIUM CELL; EX VIVO STUDY; GENE OVEREXPRESSION; IN VITRO STUDY; KIDNEY CELL; MALE; NONHUMAN; RABBIT; TRANSPORT KINETICS;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CLOPROSTENOL; CORNEA; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EPITHELIUM, CORNEAL; ERYTHROMYCIN; MALE; PERMEABILITY; PROSTAGLANDINS F, SYNTHETIC; RABBITS;

EID: 77149147408     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0049     Document Type: Article

References (37)

1. Macha, S., Hughes, P.M., and Mitra, A.K. Overview of ocular drug delivery. In: Mitra, A.K., ed. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker; 2003; p. 1-12.
2. Dey, S., Gunda, S., and Mitra, A.K. Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. J. Pharmacol. Exp. Ther. 311:246-255, 2004.
3. Hariharan, S., Gunda, S., Mishra, G.P., et al. Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm. Res. 26:1270-1282, 2009.
4. Dey, S., Patel, J., Anand, B.S., et al. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest. Ophthalmol. Vis. Sci. 44:2909-2918, 2003.
5. Karla, P.K., Earla, R., Boddu, S.H., et al. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr. Eye Res. 34:1-9, 2009.
6. Karla, P.K., Pal, D., and Mitra, A.K. Molecular evidence and functional expression of multidrug resistance associated protein (MRP) in rabbit corneal epithelial cells. Exp. Eye Res. 84:53-60, 2007.
7. Karla, P.K., Pal, D., Quinn, T., et al. Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int. J. Pharm. 336:12-21, 2007.
8. Karla, P.K., Quinn, T.L., Herndon, B.L., et al. Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux. J. Ocul. Pharmacol. Ther. 25:121-132, 2009.
9. Xiang, C.D., Batugo, M., Gale, D.C., et al. Characterization of human corneal epithelial cell model as a surrogate for corneal permeability assessment: metabolism and transport. Drug Metab. Dispos. 37:992-998, 2009.
10. Zhang, T., Xiang, C.D., Gale, D., et al. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metab. Dispos. 36:1300-1307, 2008.
11. Reid, G., Wielinga, P., Zelcer, N., et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl. Acad. Sci. USA. 100:9244-9249, 2003.
12. Wielinga, P.R., van der Heijden, I., Reid, G., et al. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J. Biol. Chem. 278:17664-17671, 2003.
13. Evers, R., Cnubben, N.H., Wijnholds, J., et al. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett. 419:112-116, 1997.
14. Cui, Y., Konig, J., Buchholz, J.K., et al. Drug resistance and ATPdependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55:929-937, 1999.
15. Jedlitschky, G., Leier, I., Buchholz, U., et al. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance- associated protein. Cancer Res. 54:4833-4836, 1994.
16. Leier, I., Jedlitschky, G., Buchholz, U., et al. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 269:27807-27810, 1994.
17. Borst, P., and Elferink, R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71:537-592, 2002.
18. Cantor, L.B. Clinical pharmacology of bimatoprost. Expert Opin. Drug Metab. Toxicol. 1:151-157, 2005.
19. Chen, J., Senior, J., Marshall, K., et al. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br. J. Pharmacol. 144:493-501, 2005.
20. Matias, I., Chen, J., De Petrocellis, L., et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J. Pharmacol. Exp. Ther. 309:745-757, 2004.
21. Woodward, D.F., Krauss, A.H., Chen, J., et al. The pharmacology of bimatoprost (Lumigan). Surv. Ophthalmol. 45(Suppl 4):S337-S345, 2001.
22. Sharif, N.A., Kelly, C.R., and Crider, J.Y. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J. Ocul. Pharmacol. Ther. 18:313-324, 2002.
23. Sharif, N.A., Williams, G.W., and Kelly, C.R. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur. J. Pharmacol. 432:211-213, 2001.
24. Woodward, D.F., Krauss, A.H., Chen, J., et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J. Pharmacol. Exp. Ther. 305:772-785, 2003.
25. Stjernschantz, J.W. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 42:1134-1145, 2001.
26. Waugh, J., and Jarvis, B. Travoprost. Drugs Aging. 19:465-471, 2002.
27. Sharif, N.A., Kelly, C.R., Crider, J.Y., et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affi nities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19:501-515, 2003.
28. Ota, T., Aihara, M., Saeki, T., et al. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 47:3395-3399, 2006.
29. Gagliuso, D.J., Wang, R.F., Mittag, T.W., et al. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. Arch Ophthalmol. 122:1342-1347, 2004.
30. Gandolfi , S.A., and Cimino, L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 110:609-614, 2003.
31. Alm, A., Grierson, I., and Shields, M.B. Side effects associated with prostaglandin analog therapy. Surv. Ophthalmol. 53(Suppl 1):S93-S105, 2008.
32. Cheng, Y., and Prusoff, W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108, 1973.
33. Mishima, S., Gasset, A., Klyce, S.D., Jr., et al. Determination of tear volume and tear flow. Invest. Ophthalmol. 5:264-276, 1966.
34. Agarwal, S., Pal, D., and Mitra, A.K. Both P-gp and MRP2 mediate transport of lopinavir, a protease inhibitor. Int. J. Pharm. 339:139-147, 2007.
35. Agarwal, S., Boddu, S.H., Jain, R., et al. Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. Int. J. Pharm. 359:7-14, 2008.
36. Jain, R., Agarwal, S., Majumdar, S., et al. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIVprotease inhibitor saquinavir by prodrug modification. Int. J. Pharm. 303:8-19, 2005.
37. Katragadda, S., Talluri, R.S., and Mitra, A.K. Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: an approach involving peptide transporter-mediated influx across rabbit cornea. J. Ocul. Pharmacol. Ther. 22:110-120, 2006.